Incannex Healthcare Completes phase 2 clinical trial of IHL-42X
- Incannex Healthcare (IHL) completes the phase two trial of its cannabinoid combination drug IHL-42X
- The drug was used to treat 11 patients with obstructive sleep apnoea, who were given three levels of dosage, plus a placebo
- Results showed patients given the lowest dose had the best outcome, with a significant reduction in the number of times their airways were blocked in the night
- Due to the positive outcome using the lowest dose, it means the company has now overcome the hurdle of treating patients, while keeping their THC levels below the legal limit for driving the following day
- IHL shares are up 7.33 per cent, trading at 40.3 cents at 2:42 pm AEST
